870812-31-0

Basic information

• Product Name: (R)-3-amino-N,N-dimethyl-4-(phenylthio)butanamide
• Synonyms: (R)-3-amino-N,N-dimethyl-4-(phenylthio)butanamide;ButanaMide, 3-aMino-N,N-diMethyl-4-(phenylthio)-, (3R)-
• CAS NO: 870812-31-0
• Molecular Formula: C₁₂H₁₈N₂OS
• Molecular Weight: 238.35
• Mol File: 870812-31-0.mol

Chemical Properties

• Appearance: /
• Density: 1.13
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (R)-3-amino-N,N-dimethyl-4-(phenylthio)butanamide(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-3-amino-N,N-dimethyl-4-(phenylthio)butanamide(870812-31-0)
• EPA Substance Registry System: (R)-3-amino-N,N-dimethyl-4-(phenylthio)butanamide(870812-31-0)

Safety Data

• Hazardous Substances Data: 870812-31-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(R)-3-amino-N,N-dimethyl-4-(phenylthio)butanamide is used as a potential active pharmaceutical ingredient for the development of new drugs, leveraging its unique structural features to target specific biological pathways or receptors.
Used in Organic Synthesis:
In the field of organic synthesis, (R)-3-amino-N,N-dimethyl-4-(phenylthio)butanamide serves as a valuable intermediate or building block for the synthesis of more complex organic molecules, including other pharmaceuticals, agrochemicals, or specialty chemicals.
Further research is necessary to fully understand the properties and potential uses of (R)-3-amino-N,N-dimethyl-4-(phenylthio)butanamide, as its chiral nature and functional groups may offer unique opportunities in various applications.

Upstream product

• 870812-29-6 benzyl (1R)-3-(dimethylamino)-1-(hydroxymethyl)-3-oxopropylcarbamate 
• 870812-30-9 benzyl {(1R)-3-(dimethylamino)-3-oxo-1-[(phenylthio)methyl]propyl}carbamate 

Downstream Products

• 870812-32-1 (R)-N¹,N¹-dimethyl-4-(phenylthio)butane-1,3-diamine 
• 406233-34-9 (R)-N,N-dimethyl-3-(2-nitro-4-sulfamoylphenylamino)-4-phenylsulfanylbutyramide 
• 1027345-13-6 (R)-N,N-dimethyl-4-(phenylthio)-3-(4-sulfamoyl-2-(trifluoromethylsulfonyl)phenylamino)butanamide 
• 1215325-46-4 ethyl 4((R)-1-(dimethylcarbamoyl)-3-(phenylthio)propan-2-ylamino)-8-(trifluoromethyl)quinoline-3-carboxylate 
• 1215325-47-5 ethyl 4-((R)-1-(dimethylcarbamoyl)-3-(phenylthio)propan-2-ylamino)-6-fluoro quinoline-3-carboxylate 
• 406233-35-0 4-(((1R)-3-(dimethylamino)-1-((phenylthio)methyl)propyl)amino)-3-nitrobenzenesulfonamide 

Relevant articles and documents

CHEMICAL COMPOUNDS

The present invention relates to compounds of Formula (I): and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds inhibit Bcl-2 and/or Bcl-XL activities and may be used for the treatment of cancer.

Design and synthesis of some new quinoline-3-carbohydrazone derivatives as potential antimycobacterial agents

A series of 26 new quinoline derivatives carrying active pharmacophores has been synthesized and evaluated for their in vitro antituberculosis activity against Mycobacterium tuberculosis H37Rv (MTB), Mycobacterium smegmatis (MC2), and Mycobacterium fortuitum following the broth micro dilution assay method. Compounds 13e, 13i, 13k, 14a, 14c, 14i, and 14k exhibited significant minimum inhibition concentrations, when compared with first line drugs isoniazid (INH) and rifampicin (RIF) and could be ideally suited for further modifications to obtain more efficacious compounds in the fight against multi-drug resistant tuberculosis.

APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

BCL-2 INHIBITORS CONTAINING A ZINC BINDING MOIETY

The present invention relates to Bcl-2 inhibitors and their use in the treatment of cell proliferative diseases such as cancer. The compounds of the invention may further act as HDAC inhibitors

BCL-2 INHIBITORS

The present invention relates to Bcl-2 inhibitors and their use in the treatment of cell proliferative diseases such as cancer.

ARYLSULFONAMIDE COMPOUNDS

The invention relates generally to small molecules that mimic the biological activity of certain peptides and proteins, to compositions containing them and to their use. In particular, the invention relates to compounds of the general formula (I) that mim

N-sulfonylcarboximidamide apoptosis promoters

Compounds having the formula are apoptosis promoters. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.